Cortexyme completes Novosteo acquisition for ~6M shares; CLO departing

Quince Therapeutics, Inc.

Completed merger with Novosteo; each Novosteo share converted to 0.0911 Cortexyme shares.
Issued approximately 6 million shares (including options covering 507,108 shares) as consideration.
Caryn McDowell, Chief Legal and Administrative Officer, to depart effective July 8, 2022.
McDowell receives $339,000 cash severance, accelerated vesting, and extended option exercise period.
Additional severance and benefits if change in control occurs within 3 months after departure.

item 2.01 item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Caryn McDowell

Chief Legal and Administrative Officer and Corporate Secretary

QNCX · Quince Therapeutics, Inc.

Effective: 2022-07-08
Filed: May 20, 2022, 7:59 PM ET

On May 20, 2022, the Company announced the departure of Caryn McDowell, the Company’s Chief Legal and Administrative Officer and Corporate Secretary, effective as of July 8, 2022 (the “Departure Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Caryn McDowell departed as Chief Legal and Administrative Officer and Corporate Secretary at Quince Therapeutics, Inc..

Action: departed
Role: Chief Legal and Administrative Officer and Corporate Secretary

Exact text from the filing

On May 20, 2022, the Company announced the departure of Caryn McDowell, the Company’s Chief Legal and Administrative Officer and Corporate Secretary, effective as of July 8, 2022 (the “Departure Date”).

View on SEC.gov

Quince Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-155640

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.